Is Regeneron a Top AI Healthcare Stock Hedge Funds Love?
Hedge funds are eyeing AI-powered healthcare plays. Here's where Regeneron stands in that crowded field.
Regeneron Pharmaceuticals has long been a hedge fund darling, and the conversation is shifting toward which biotech names carry real artificial intelligence horsepower underneath the hood. The question isn't just whether REGN is a good stock — it's whether it belongs in the same breath as the AI-driven healthcare names that institutional money is quietly stacking.
Hedge funds aren't throwing darts right now. They're looking for companies where AI accelerates drug discovery, streamlines clinical trials, or sharpens diagnostics in ways that compress timelines and fatten margins. Regeneron has built serious computational biology infrastructure over the years, and that gives it a credible seat at the table when the AI-in-healthcare conversation heats up.
Read more BofA Keeps Apple Buy Rating, Sees AI Upgrade Cycle Ahead →
That said, the competitive landscape is brutal. You're not just comparing REGN to traditional pharma peers anymore. Pure-play AI healthcare names and well-capitalized biotechs with fresh AI partnerships are all fighting for the same institutional allocation dollars. Hedge funds are ranking these names, and where Regeneron lands on that list matters for how retail traders should be thinking about positioning.
The smart play here is watching what the big money actually does — not what it says. Hedge fund filings give you a lagging but real signal on conviction. If REGN is showing up consistently in top-holdings lists alongside explicitly AI-forward healthcare names, that tells you something about how sophisticated investors are categorizing the stock. Ignore that signal at your own risk.
Continue reading at Yahoo Finance
